We have a new antibiotic in the arsenal to help fight the life-threatening infections associated with cystic fibrosis.
The FDA approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) for the treatment of CF. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including an early $1 million investment to help develop the therapy.
Developed by Gilead Sciences, Inc., Cayston offers a much-needed antibiotic alternative for CF patients who battle recurrent lung infections and develop resistance to existing antibiotics.
Cayston is administered with a new device called Altera that allows patients to take the medicine in less than five minutes, a fraction of the time required for other inhaled antibiotics.
This shortened delivery time reduces the burden on patients, who -- on average -- have a treatment regimen of three to four hours per day.
Cayston will be available by the end of next week. Patients interested in learning more about Cayston should consult their physicians.
The approval of Cayston demonstrates that our drug development model, fueled by donors and volunteers like you, is working and making a real difference in the lives of people with cystic fibrosis.